68Ga prostate-specific membrane antigen positron emission tomography for evaluation of biochemical recurrence of prostate cancer - our local experience

Abstract

pathway (Akt, p-Akt, mTOR and p-mTOR) as well as proliferation and apoptosis makers were evaluated by immunohistochemistry in xenografts from both animal models. Results: Both s.c. and orthotopic xenografts from PC-3M-CD44v6-KD cells displayed supressed tumour growth and increased responsiveness to docetaxel (40mg/kg, ip) and radiation (2Gy/day for 4 consecutive days) compared to control xenografts from PC-3M-CD44v6-scr cells in NOD/SCID mice. Down-regulation of the PI3K/Akt/mTOR pathway proteins (p-Akt and p-mTOR), proliferation marker (Ki-67) and angiogenesis marker (CD31), as well as up-regulation of apoptotic responses (Caspase-3) to chemotherapy, DNA damage responses (?-H2AX) to radiation were found in PC-3M-CD44v6-KD xenografts, respectively. Conclusions: CD44v6 is actively involved in CaP tumorigenesis and treatment responses to chemo-/radio-therapy via the PI3K/Akt/mTOR signalling pathway in in vivo mouse models and holds promise as a therapeutic target for the treatment of CaP.

Current Status and Growth of Nuclear Theranostics in Singapore

“…Prostate-specific membrane antigen radioligand PET (PSMA PET) was introduced in Singapore General Hospital in August 2015 using 68Ga-PSMA-11. Retrospective review of our initial results are largely in line with published data and affirm the high sensitivity of PSMA PET for the evaluation of biochemical recurrence of prostate cancer, even at low PSA [17]. The use of PSMA PET in the primary staging of prostate cancer also identified a significant number of lymph node and bone metastases, especially in patients with intermediate to high risk (PSA > 10 and Gleason score > 7).…”